Long-Term Safety and Tolerability of BMP7 and HGF Gene Overexpression in Rabbit Cornea

Overview

Journal Transl Vis Sci Technol

Specialties Biomedical Engineering
Ophthalmology

Date 2021 Aug 12

PMID 34383876

Citations 5

Authors

Suneel Gupta

Nishant R Sinha

Lynn M Martin

Landon M Keele

Prashant R Sinha

Jason T Rodier

James R Landreneau

Nathan P Hesemann

Rajiv R Mohan

Affiliations

Soon will be listed here.

Abstract

Purpose: Tissue-targeted localized BMP7+HGF genes delivered into the stroma via nanoparticle effectively treats corneal fibrosis and rehabilitates transparency in vivo without acute toxicity. This study evaluated the long-term safety and tolerability of BMP7+HGF nanomedicine for the eye in vivo.

Methods: One eye each of 36 rabbits received balanced salt solution (group 1, naïve; n = 12), naked vector with polyethylenimine-conjugated gold nanoparticles (PEI2-GNP; group 2, naked-vector; n = 12), or BMP7+HGF genes with PEI2-GNP (group 3, BMP7+HGF; n = 12) via a topical delivery technique. Safety and tolerability measurements were performed by clinical biomicroscopy in live rabbits at predetermined time intervals up to 7 months. Corneal tissues were collected at 2 months and 7 months after treatment and subjected to histology, immunofluorescence, and quantitative real-time PCR analyses.

Results: Clinical ophthalmic examinations and modified MacDonald-Shadduck scores showed no significant changes in corneal thickness (P = 0.3389), tear flow (P = 0.2121), intraocular pressure (P = 0.9958), epithelial abrasion, or ocular abnormality. Slit-lamp, stereo, confocal, and specular biomicroscopy showed no signs of blepharospasm chemosis, erythema, epiphora, abnormal ocular discharge, or changes in epithelium, stroma, and endothelium after BMP7+HGF therapy for up to 7 months, as compared with control groups. Throughout the 7-month period, no significant changes were recorded in endothelial density (P = 0.9581). Histological and molecular data were well corroborated with the subjective clinical analyses and showed no differences in the naïve, naked-vector, and BMP7+HGF groups.

Conclusions: Localized BMP7+HGF therapy is a safe, tolerable, and innovative modality for the treatment of corneal fibrosis.

Translational Relevance: Nanoparticle-mediated BMP7+HGF combination gene therapy has the potential to treat corneal fibrosis in vivo without short- or long-term toxicity.

Citing Articles

Analysis of Smad3 in the modulation of stromal extracellular matrix proteins in corneal scarring after alkali injury.

Gupta S, Zhang E, Sinha S, Martin L, Varghese T, Forck N Mol Vis. 2025; 30:448-464.

PMID: 39959170 PMC: 11829792.

Modulating Growth Factor Receptor Signaling to Promote Corneal Epithelial Homeostasis.

Tarvestad-Laise K, Ceresa B Cells. 2023; 12(23).

PMID: 38067157 PMC: 10706396. DOI: 10.3390/cells12232730.

Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy.

Wei J, Mu J, Tang Y, Qin D, Duan J, Wu A J Nanobiotechnology. 2023; 21(1):282.

PMID: 37598148 PMC: 10440041. DOI: 10.1186/s12951-023-01974-4.

Carbofuran pesticide toxicity to the eye.

Kempuraj D, Zhang E, Gupta S, Gupta R, Sinha N, Mohan R Exp Eye Res. 2022; 227:109355.

PMID: 36572166 PMC: 9918712. DOI: 10.1016/j.exer.2022.109355.

Corneal fibrosis abrogation by a localized AAV-mediated inhibitor of differentiation 3 (Id3) gene therapy in rabbit eyes in vivo.

Gupta S, Fink M, Kempuraj D, Sinha N, Martin L, Keele L Mol Ther. 2022; 30(10):3257-3269.

PMID: 35780298 PMC: 9552811. DOI: 10.1016/j.ymthe.2022.06.018.

References

. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(9995):743-800. PMC: 4561509. DOI: 10.1016/S0140-6736(15)60692-4. View

Mohan R, Sharma A, Netto M, Sinha S, Wilson S . Gene therapy in the cornea. Prog Retin Eye Res. 2005; 24(5):537-59. DOI: 10.1016/j.preteyeres.2005.04.001. View

Goswami R, Subramanian G, Silayeva L, Newkirk I, Doctor D, Chawla K . Gene Therapy Leaves a Vicious Cycle. Front Oncol. 2019; 9:297. PMC: 6491712. DOI: 10.3389/fonc.2019.00297. View

Mohan R, Tandon A, Sharma A, Cowden J, Tovey J . Significant inhibition of corneal scarring in vivo with tissue-selective, targeted AAV5 decorin gene therapy. Invest Ophthalmol Vis Sci. 2011; 52(7):4833-41. PMC: 3175954. DOI: 10.1167/iovs.11-7357. View

Farid M, Rhee M, Akpek E, Amescua G, Garcia-Ferrer F, Lin A . Corneal Edema and Opacification Preferred Practice Pattern®. Ophthalmology. 2018; 126(1):P216-P285. DOI: 10.1016/j.ophtha.2018.10.022. View

Thomas M, Klibanov A . Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc Natl Acad Sci U S A. 2003; 100(16):9138-43. PMC: 170885. DOI: 10.1073/pnas.1233634100. View

Weiskirchen R, Meurer S, Gressner O, Herrmann J, Borkham-Kamphorst E, Gressner A . BMP-7 as antagonist of organ fibrosis. Front Biosci (Landmark Ed). 2009; 14(13):4992-5012. DOI: 10.2741/3583. View

Mohan R, Tovey J, Sharma A, Schultz G, Cowden J, Tandon A . Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS One. 2011; 6(10):e26432. PMC: 3198476. DOI: 10.1371/journal.pone.0026432. View

Tandon A, Sharma A, Rodier J, Klibanov A, Rieger F, Mohan R . BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo. PLoS One. 2013; 8(6):e66434. PMC: 3682981. DOI: 10.1371/journal.pone.0066434. View

10.

Wilson S, Chen L, Mohan R, Liang Q, Liu J . Expression of HGF, KGF, EGF and receptor messenger RNAs following corneal epithelial wounding. Exp Eye Res. 1999; 68(4):377-97. DOI: 10.1006/exer.1998.0603. View

11.

Gupta S, Rodier J, Sharma A, Giuliano E, Sinha P, Hesemann N . Targeted AAV5-Smad7 gene therapy inhibits corneal scarring in vivo. PLoS One. 2017; 12(3):e0172928. PMC: 5365107. DOI: 10.1371/journal.pone.0172928. View

12.

Mathews P, Lindsley K, Aldave A, Akpek E . Etiology of Global Corneal Blindness and Current Practices of Corneal Transplantation: A Focused Review. Cornea. 2018; 37(9):1198-1203. DOI: 10.1097/ICO.0000000000001666. View

13.

Menko A, Walker J, Stepp M . Fibrosis: Shared Lessons From the Lens and Cornea. Anat Rec (Hoboken). 2019; 303(6):1689-1702. PMC: 6697240. DOI: 10.1002/ar.24088. View

14.

Gothelf A, Eriksen J, Hojman P, Gehl J . Duration and level of transgene expression after gene electrotransfer to skin in mice. Gene Ther. 2010; 17(7):839-45. DOI: 10.1038/gt.2010.35. View

15.

Miyagi H, Thomasy S, Russell P, Murphy C . The role of hepatocyte growth factor in corneal wound healing. Exp Eye Res. 2017; 166:49-55. PMC: 5831200. DOI: 10.1016/j.exer.2017.10.006. View

16.

Friedlander M . Fibrosis and diseases of the eye. J Clin Invest. 2007; 117(3):576-86. PMC: 1804382. DOI: 10.1172/JCI31030. View

17.

Huang J, Maram J, Tepelus T, Modak C, Marion K, Sadda S . Comparison of manual & automated analysis methods for corneal endothelial cell density measurements by specular microscopy. J Optom. 2017; 11(3):182-191. PMC: 6039579. DOI: 10.1016/j.optom.2017.06.001. View

18.

Zyablitskaya M, Jayyosi C, Takaoka A, Myers K, Suh L, Nagasaki T . Topical Corneal Cross-Linking Solution Delivered Via Corneal Reservoir in Dutch-Belted Rabbits. Transl Vis Sci Technol. 2020; 9(9):20. PMC: 7442877. DOI: 10.1167/tvst.9.9.20. View

19.

Mohan R, Schultz G, Hong J, Mohan R, Wilson S . Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access. Exp Eye Res. 2003; 76(3):373-83. DOI: 10.1016/s0014-4835(02)00275-0. View

20.

Robaei D, Watson S . Corneal blindness: a global problem. Clin Exp Ophthalmol. 2014; 42(3):213-4. DOI: 10.1111/ceo.12330. View